We have located links that may give you full text access.
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
Single-Acquisition Triple-Bolus Dual-Energy CT Protocol for Comprehensive Evaluation of Renal Masses: A Single-Center Randomized Noninferiority Trial.
AJR. American Journal of Roentgenology 2018 July
OBJECTIVE: The primary objective of this study was to compare triple-bolus dual-energy CT (DECT) against standard triple-phase MDCT in terms of appropriateness of patient treatment.
SUBJECTS AND METHODS: One hundred twenty-four patients with suspected renal masses seen at ultrasound were randomized into triple-bolus DECT and triple-phase MDCT groups. Patients in the triple-bolus DECT group underwent synchronous corticomedullary nephrographic delayed-phase triple-bolus DECT. In the triple-phase MDCT group, single-energy triple-phase scans were acquired after an unenhanced scan. The primary outcome was appropriateness of treatment received at 1 year. The predefined noninferiority limit was 10%. Histopathologic analysis or follow-up confirmed the benign or malignant nature of the masses. Diagnostic accuracy to differentiate benign from malignant masses was calculated. Size-specific dose estimates were compared.
RESULTS: After excluding six patients, 118 patients were analyzed (62 triple-bolus DECT; 56 triple-phase MDCT). Treatment appropriateness was not significantly different (p = 0.9397) between the two groups (61/62 [98.39%; 95% CI, 95.26-101.52%] for triple-bolus DECT vs 55/56 [98.21%; 95% CI, 94.74-101.68%] for triple-phase MDCT). The absolute difference was 0.18% (95% CI, -4.48% to 4.84%). Both techniques had similar diagnostic accuracy (sensitivity, 98.25% vs 96.67%; specificity, 98.17% vs 97.97%). The mean (± SD) size-specific dose estimate was significantly lower for triple-bolus DECT than for triple-phase MDCT (19.02 ± 4.07 vs 57.04 ± 15.17 mGy; p < 0.0001).
CONCLUSION: Single-acquisition triple-bolus DECT is noninferior to triple-phase MDCT, with similar diagnostic accuracy but delivering significantly less radiation.
SUBJECTS AND METHODS: One hundred twenty-four patients with suspected renal masses seen at ultrasound were randomized into triple-bolus DECT and triple-phase MDCT groups. Patients in the triple-bolus DECT group underwent synchronous corticomedullary nephrographic delayed-phase triple-bolus DECT. In the triple-phase MDCT group, single-energy triple-phase scans were acquired after an unenhanced scan. The primary outcome was appropriateness of treatment received at 1 year. The predefined noninferiority limit was 10%. Histopathologic analysis or follow-up confirmed the benign or malignant nature of the masses. Diagnostic accuracy to differentiate benign from malignant masses was calculated. Size-specific dose estimates were compared.
RESULTS: After excluding six patients, 118 patients were analyzed (62 triple-bolus DECT; 56 triple-phase MDCT). Treatment appropriateness was not significantly different (p = 0.9397) between the two groups (61/62 [98.39%; 95% CI, 95.26-101.52%] for triple-bolus DECT vs 55/56 [98.21%; 95% CI, 94.74-101.68%] for triple-phase MDCT). The absolute difference was 0.18% (95% CI, -4.48% to 4.84%). Both techniques had similar diagnostic accuracy (sensitivity, 98.25% vs 96.67%; specificity, 98.17% vs 97.97%). The mean (± SD) size-specific dose estimate was significantly lower for triple-bolus DECT than for triple-phase MDCT (19.02 ± 4.07 vs 57.04 ± 15.17 mGy; p < 0.0001).
CONCLUSION: Single-acquisition triple-bolus DECT is noninferior to triple-phase MDCT, with similar diagnostic accuracy but delivering significantly less radiation.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app